F8 and hemophilia A: Emicizumab has low immunogenicity, with anti-drug antibodies (ADAs) reported in 34 (5.1%) of 668 male hemophilia A patients with and without FVIII inhibitors, which were pooled from seven phase 3/3b clinical studies (HAVEN 1–5, HOHOEMI, and STASEY).